CymaBay Therapeutics to Participate in Upcoming Investment Conferences
NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates’ 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global Biopharma Conference, March 11-13, in Miami, Florida.
Related news for (CBAY)
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis